Therapeutic options for extended-spectrum β-lactamases (ESBLs), AmpC β-lactamases producing Escherichia coli and Klebsiella sp. isolated from various clinical samples

Escherichia coli and Klebsiella sp. are the predominant species isolated from clinical samples. Recent proper understanding of antibiotic susceptibility pattern extended-spectrum β-lactamases (ESBL) AmpC (AmpC) producing E. will prevent distribution future incidence ESBL AmpC. We designed this study to understand patterns a tertiary care hospital in North India. A cross-sectional was conducted March 2021 February 2022. Guring period, various samples were collected further tested for by using Double disc Synergy test, whereas detected Boronic acid disk potentiation method. Their noted. Various specimens collected, which 37.95% shown growth bacteria. Among them, 46.67% 25.21% identified standard laboratory protocol. isolates 44.37% 34.20% sp., respectively. Whereas production 18.27% 29.36% pus, blood, sputum showed highest sensitivity towards colistin, tigecycline, imipenem while urine imipenem, meropenem sensitivity. Susceptibility enhance infection management help clinicians prescribe appropriate antibiotics. The carbapenem, nitrofurantoin, colistin tigecycline susceptible against